Breakthrough pain in cancer is an intense, sudden pain that is often unpredictable and debilitating and occurs despite otherwise appropriate opioid therapy, Archimedes Pharma reported.
During the rest of 2011, the company said Lazanda will be available through a Risk Evaluation and Mitigation Strategy program.
Read the FDA report on Lazanda.
Read the Archimedes Pharma release on Lazanda.
Related Articles on FDA Approvals:
FDA Clears New Version of PillCam for Esophageal Mucosa
Expected Approval of Minimally Invasive Aortic Devices Will Spark Boom
FDA Pressed to Speed Up Device OKs Before Fee Reauthorization
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
